UCB Stock Other OTC
Stocks
UCBJF
BE0003739530
Pharmaceuticals
OTC Markets Traded| Market Cap | 48.85B 55.61B 45B 42.08B 78.92B 5,247B 80.37B 540B 209B 2,587B 209B 204B 8,989B | P/E 2026 * |
27.6x | P/E 2027 * | 21.4x |
|---|---|---|---|---|---|
| Enterprise Value | 47.74B 54.34B 43.98B 41.12B 77.13B 5,128B 78.54B 528B 204B 2,528B 204B 200B 8,784B | EV / Sales 2026 * |
5.6x | EV / Sales 2027 * | 4.76x |
| Free-Float |
61.59% | Yield 2026 * |
0.57% | Yield 2027 * | 0.59% |
Last Transcript: UCB
| 1 day | -0.39% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 59 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -.--% | - | - | 55.14B | |
| -0.53% | +1.67% | +19.19% | -20.47% | 63.43B | |
| +0.07% | +38.60% | +38.60% | +38.60% | 41.58B | |
| -1.13% | -0.10% | -51.58% | -58.50% | 37.99B | |
| +1.19% | +2.74% | +58.64% | -29.02% | 29.47B | |
| -1.11% | -6.58% | +122.45% | -49.58% | 23.97B | |
| -0.86% | +9.48% | +59.19% | +72.19% | 21.67B | |
| -2.17% | -1.26% | -5.34% | +140.00% | 17.28B | |
| -0.25% | +6.77% | +69.55% | +122.96% | 16.7B | |
| +0.48% | +5.16% | +57.03% | +345.02% | 13.58B | |
| Average | -0.49% | +3.33% | +40.86% | +62.36% | 29.52B | |
| Weighted average by Cap. | -0.45% | +2.98% | +32.57% | +25.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.52B 9.7B 7.85B 7.34B 13.77B 916B 14.02B 94.22B 36.49B 451B 36.44B 35.64B 1,568B | 9.62B 10.96B 8.87B 8.29B 15.55B 1,034B 15.83B 106B 41.2B 510B 41.14B 40.24B 1,771B |
| Net income | 1.75B 1.99B 1.61B 1.5B 2.82B 187B 2.87B 19.29B 7.47B 92.41B 7.46B 7.3B 321B | 2.3B 2.62B 2.12B 1.98B 3.72B 247B 3.79B 25.46B 9.86B 122B 9.85B 9.63B 424B |
| Net Debt | -1.11B -1.27B -1.02B -958M -1.8B -119B -1.83B -12.29B -4.76B -58.87B -4.75B -4.65B -205B | -3.06B -3.48B -2.82B -2.63B -4.94B -328B -5.03B -33.8B -13.09B -162B -13.07B -12.78B -563B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
